Pharmacokinetic study of the interaction between natural equol supplement and hormone therapy drugs for breast cancer

Pharmacokinetic study of the interaction between natural equol supplement "EQUELLE" and hormone therapy drugs for breast cancer in healthy female volunteers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031200084

Enrollment

Registered

2020-08-13

Start date

2020-09-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

Tamoxifen 20mg or anastrozole 1mg or letrozole 2.5mg or exemestane 25mg given on day1 and day15. Equol supplement also given from day 9 to 15.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Postmenopausal women 2. Weight more than or equal to 40kg 3. Body mass index between 17.6 and 30.0 kg/m2

Exclusion criteria

Exclusion criteria: 1. Breast cancer patients 2. Pregnant women 3. Lactating women 4. Having Soy allergy 5. History or presence of clinically significant neurologic, cranial nerve, cardiovascular, respiratory, hepatic, renal, endocrine or metabolic disorder

Design outcomes

Primary

Measure	Time frame
Impact of Equol supplement on exposure of hormone therapy drugs for breast cancer	—

Contacts

Public ContactChiyo Imamura

Showa University

imamurack@med.showa-u.ac.jp+81-3-3784-8145

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026